Monday, June 5, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

BARDA Awards Medical Countermeasures Clinical Studies Network Contracts

by Global Biodefense Staff
October 20, 2020
BARDA Awards Medical Countermeasures Clinical Studies Network Contracts

Credit: HHS/ASPR/BARDA

New contract awards by the Biomedical Advanced Research and Development Authority (BARDA) will support three integrated components of the Medical Countermeasures Clinical Studies Network (CSN) to provide federal partners and medical countermeasure developers with technical and regulatory assistance in the development of vaccines, therapeutics, diagnostics, and medical devices to prevent or treat the medical consequences of chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases.

BARDA established the CSN as a core service in 2012 and awarded IDIQ contracts to five full service clinical Contract Research Organizations in 2014 to form the CSN infrastructure. During the network’s five years, several important gaps in capabilities were identified. Three separate and distinct solicitations have been awarded to address the following gaps: Clinical Trial Planning & Execution services on a routine basis to address the requirements under regular non-emergency timelines, as well as services during emergencies when rapid timelines are crucial; a Biological Specimen and Investigational Product storage facility; and a Statistical and Data Coordinating Center.

The Clinical Trials Planning and Execution (CTPE) component will be responsible for planning and execution of clinical studies to support medical countermeasure development and was awarded to four recipients:

  • ICON Government & Public Health Solutions
  • Pharm-Olam LLC
  • PRA Health Sciences, Inc.
  • Technical Resources International, Inc.

The Statistical Data Coordinating Center (SDC) will serve to standardize data collection, management, and analysis across studies that use this BARDA-supported network and was awarded to:

  • Rho Federal Systems Division, Inc.

The Biological Specimen and Investigational Product Storage Facility (BSIP) will provide a single facility for long-term storage of clinical study specimens and investigational products across BARDA-supported studies was awarded to:

  • ATCC Federal Solutions
Tags: ASPRAwardsBARDAClinical TrialsEditor PickHHSPublic Health EmergencySelect Agents

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy